News
National brain tumour research funding needs to increase to £35 million a year
Your legacy could help find a cure

This
week is Remember A Charity Week in the UK, giving charities the chance to share
with supporters what a difference a gift in
their will could make.
In
2022 almost 16% of wills processed included a gift to charity and conservative
estimates predict that the final legacy income figure for 2022 will sit at
around £3.5 billion.
With
one in three people knowing someone affected by this devastating disease and
with brain tumours continuing to kill more children and adults under the age of
40 than any other cancer, the need for sustained funding of our research is
more important now than ever.
Leaving
a gift to charity in your will is one of the best ways to protect the causes
you care about. Not only can your legacy look after your loved ones after you
are gone, it could help to transform the future of brain tumour research.
Your
legacy could help to ensure the sustainability of our research programmes
enabling continuous research, bringing hope of better treatments and outcomes
for future families. It could support our campaigning for greater investment,
helping to achieve parity with better funded cancers such as breast and
leukaemia.
Russell
Marriott, our Director of Income Generation and Development, said: “With 60%
of UK adults not having a valid will in place, we are asking our supporters to
consider what a difference a gift in your will – no matter how large or small –
could make.
“We’ve
teamed up with the National Free Wills Network to provide our supporters with
the opportunity to have a simple and uncomplicated will written for free via a
local solicitor in their area. There is no obligation to leave a gift to Brain
Tumour Research when using this service, however, we would be extremely
grateful if you would consider a gift to help sustain our vital work.”
Related
reading:
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.